Phase 1Completed
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
- Sponsor
- Cell>Point LLC (Industry)
- Enrollment
- 4 enrolled
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose); Technetium 99m ethylenedicysteine-deoxyglucose; 18 F fluorodeoxyglucose
- Ages
- adults, older adults
- Registry
- NCT00864110
Full record on ClinicalTrials.gov
From the registry
This is a multi-center Phase 1 b study designed to expand the patient safety using 99mTc-EC-DG with SPECT/CT imaging and to expand the patient radiation dosimetry and pharmacokinetic database using 99mTc-EC-DG in patients who have non-incisional biopsy definitive evidence of Non-small Cell Lung Cancer as compared to 18F-FDG PET/CT imaging.
Primary outcomes
- Safety: through adverse event collection
History
Last registry update
Study completion
Primary completion
Started
Registered